Viking Therapeutics reported results for the quarter ended 2Q 2026, posting revenue of $0 and a net loss attributable to common stockholders of $(128.0M), or a basic and diluted loss per share of $(1.10), compared with a net loss of $(65.6M) and loss per share of $(0.58) in the year‑ago quarter.
Financial Highlights
- Revenue: $0 for Q2 2026, unchanged from $0 in the year‑ago quarter.
- Net income: Net loss attributable to common stockholders of $(128.0M) for Q2 2026 vs. net loss of $(65.6M) in the year‑ago quarter (widened loss).
- Diluted EPS: Basic and diluted net loss per share $(1.10) for Q2 2026 vs. $(0.58) for Q2 2025.
Business Highlights
- Clinical program progress: Multiple VK2735 trials advanced with VANQUISH-1 and VANQUISH-2 enrollment completed; both oral and subcutaneous programs are moving forward.
- Regulatory and R&D momentum: VK2809 produced positive 52-week NASH histology results; an IND was filed for VK3019 with a Phase 1 study initiated; VK0214 showed reductions in very long chain fatty acids (VLCFA).
- Manufacturing scale-up: Multi-year agreements with CordenPharma secure API and fill/finish capacity — including autoinjectors, vials and capacity for more than 1B tablets — supported by a prepayment schedule.
- Operational spend and runway: R&D spending increased to support late-stage VK2735 trials; the company expects cash runway through at least Sept. 30, 2027.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.